NEW BRUNSWICK (Dow Jones) – The U.S. pharmaceutical and Consumer goods manufacturer Johnson & Johnson (J & J) has in the fourth quarter due to Restructuring charges recorded a decline in profits, which analysts’ expectations but surpassed. Earnings fell to 2.21 (2.71) billion USD and 0.79 (0.97) per share, as announced, the Group from New Brunswick on Tuesday. Before exceptional items increased the yield per NAV per share to 1.02 USD of 0.94 USD. Analysts had a smaller increase to 0.97 USD expected.
Sales increased from October to December increased by 9% to 16.55 USD billion, surpassing analysts also forecast 15.7 billion USD. This is half of favorable exchange rates due. Sales in the consumer business climbed by 10%. The Pharmaceutical giant, faced with rising development costs and a sluggish economic modified and streamlined cut 7% of its workforce. Also generic products important prescription Drugs were added to Johnson & Johnson and the gain diminished.
In FY 2009, the Group achieved a solid result and exceeded its profit forecast slightly. Net income before exceptional items stood at 12.9 billion USD, or USD 4.63 per share. The company had a Yield up to 4.59 USD per NAV per share forecast. The global Revenues fell by 2.9% to 61.9 billion USD. For 2010, the Group now expects profit before nonrecurring items between 4.85 USD and 4.95 USD per share. Analysts on average expected here, with U.S. $ 4.94 per share.
Websites: www.jnj.com -By Nathan Becker, Dow Jones Newswires; +49 (0) 69 29725 100, unternehmen.de @ dowjones.com DJN / DJG / sha / has Visit our website http://www.dowjones.de
(END) Dow Jones Newswires
January 26, 2010 08:46 ET (13:46 GMT)
Copyright (c) 2010 Dow Jones & Company, Inc.